Nishikawa Kazuhiro, Iwase Kazuhiro, Aono Toyokazu, Yoshida Hiroshi, Nomura Masaya, Tamagawa Hiroshi, Matsuda Chu, Deguchi Takashi, Kawada Junji, Higashi Shigeyoshi, Deguchi Koichi, Noguchi Yuki, Okumura Yuichiro, Nomura Masatoshi, Fushimi Hiroaki, Takagi Mari, Fukui Akiko, Fujitani Kazumasa, Endo Shunji, Tanaka Yasuhiro
Dept. of Surgery, Osaka General Medical Center.
Gan To Kagaku Ryoho. 2013 Nov;40(12):2259-61.
We report the case of a patient with paclitaxel (PTX) -resistant recurrent gastric cancer who was effectively treated with S-1 plus docetaxel( DOC). A 62-year-old woman underwent total gastrectomy for Stage IV advanced gastric cancer (type 4, por 2>sig, pT4a (SE), pN3a, pP1, CY1) in 2009. Although S-1 was administered as first-line chemotherapy, recurrent peritoneal metastasis was diagnosed 22 months after surgery. S-1 plus irinotecan (CPT-11) was administered as second-line chemotherapy, and this was followed by weekly PTX (80 mg/m2) as third-line chemotherapy. However, computed tomography (CT) showed increased ascites and peritoneal wall thickening in the pelvis. As the tumor proved resistant to PTX, making the treatment ineffective, S-1( 80 mg/m2, day 1-14, q3w) plus DOC( 40 mg/m2, day 1, q3w) was initiated. Two months later, the ascites and peritoneal wall thickening in the pelvis disappeared. Twelve months after initiation of S-1 plus DOC chemotherapy, no sign of recurrence has been noted.